Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?

Annals of Oncology

Volumn 12, Issue 12, 2001, Pages 1667-1670

  Soria, J C ^a   Brisgand, D ^a   Le Chevalier, T ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; Multivariate analysis; Non small cell lung cancer; Performance status; Prognostic factor

Indexed keywords

CISPLATIN; NAVELBINE; VINDESINE;

ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VINBLASTINE; VINDESINE;

EID: 0035698002     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1013574413217     Document Type: Article

References (21)

1. Cancer mortality in Europe, 1990-1994, and an overview of trends from 1955 to 1994
2. Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma
3. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer: Report of a Canadian multicenter randomized trial
4. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer
5. Polychemotherapy in advanced non-small-cell lung cancer: A meta-analysis
6. Chemotherapy versus supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature
7. Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
8. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients
9. Survival with inoperable lung cancer: An integration of prognostic variables based on simple clinical criteria
10. Prognostic factors in inoperable adenocarcinoma of the lung: A multivariate regression analysis of 259 patients
11. Pre-treatment prognostic factors in patients with stage III non-small-cell lung cancer
12. Prognostic factors for patients with advanced non-small-cell lung cancer: Univariate and multivariate analysis including recursive partitioning and amalgamation
13. Blood analyses as prognostic factors in primary lung cancer
14. The value of tumour markers in lung cancer
15. Prognostic factors for survival in patients with inoperable lung cancer
16. Prognostic factors for patients with advanced non-small-cell lung cancer: Uni and multivariate analysis including RECPAM in 1052 patients
17. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy
18. Survival determinants in extensive stage non-small-cell lung cancer: The Southwest Oncology Group Experience
19. E1594, a randomized phase III trial in metastatic non-small-cell lung cancer. Outcome of PS 2 patients: An Eastern Cooperative Group Trial
20. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small-cell lung cancer. A two-stage phase II study
21. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer